Positive-crossmatch deceased-donor real-world cohort

11 evidence topics · 1 source

Objective

Clinical-practice study objective

“short-term efficacy and safety” (opens the source at this quote in a new tab)

Location and study date

Minimum observation period

“at least 3 months of follow-up” (opens the source at this quote in a new tab)

Study design

Initial clinical-practice cohort

“the first 9 patients” (opens the source at this quote in a new tab)

Eligibility criteria

Crossmatch eligibility

“positive crossmatch” (opens the source at this quote in a new tab)

Treatment

Imlifidase exposure

“After 1 injection of imlifidase, all were negative.” (opens the source at this quote in a new tab)

Study outcomes

Rationale for using crossmatch conversion as the primary endpoint

Not applicable.

Statistical analysis description

Number of participants (Planned and analyzed)

Reported cohort size

Population	Participants
Transplanted cohort	“9”

Description of analysis sets

No evidence found.

Results

Participant disposition

No evidence found.

Baseline characteristics

Baseline calculated panel-reactive antibody

Characteristic	Quoted value
Lower reported sensitization category	“99%”
Higher reported sensitization category	“100%”

Efficacy results

Positive crossmatch against a deceased donor: crossmatch conversion

“After 1 injection of imlifidase, all were negative.” (opens the source at this quote in a new tab)

Kidney function and observation period

Outcome	Quoted value
Mean eGFR at last follow-up, mL/min/1.73 m²	“56 ± 22”
Mean follow-up, months	“7 ± 2.8”

Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results

Positive crossmatch against a deceased donor: graft loss, death, and infections

“No graft loss or death were observed. Four patients developed at least 1 infection.” (opens the source at this quote in a new tab)

Study limitations

Summary

This clinical-practice cohort comprised 9 transplanted participants with at least 3 months of follow-up. The mean reported follow-up was 7 months. Crossmatch conversion occurred after one imlifidase injection, but 4 participants developed at least one infection. The small cohort and short follow-up do not establish comparative effectiveness or long-term graft survival.